In a recent study published within the journal Nature Medicine, researchers investigated the consequences of tirzepatide, a glucagon-like peptide-1 (GLP-1) receptor agonist and glucose-dependent insulinotropic polypeptide, in bolstering weight reduction and stopping weight gain in chubby and obese patients under intensive lifestyle interventions.

Their research methodology comprised a 72-week, double-blind, randomized, 1:1, placebo-controlled trial on adults whose 12-week lifestyle interventions resulted in weight losses of 5% or greater.

The findings revealed that tirzepatide promoted additional weight reduction in these patients, with mild to moderate gastrointestinal disorders being probably the most common side effect.

Image Credit: Stock-Asso / Shutterstock

Obesity and lifestyle intervention limitations

Obesity is a worldwide condition, with over 1 billion patients affected by the non-transmissible ailment. Attributable to a mix of genetic, lifestyle, and socioeconomic aspects, chubby and obesity rates are on the rise, with the World Health Organization estimating a further 167 million patients by 2025. Chubby and obesity are accompanied by a bunch of comorbidities, including diabetes, cardiometabolic risk aspects like hypertension, osteoarthritis, and even cancer.

The gold standard in treating these conditions is intensive lifestyle interventions involving a mix of a discount in calorific intake, routine intensive physical activity, and frequent behavioral counseling by trained professionals. Generally successful at its onset, lifestyle interventions have two fundamental limitations – 1. Lower than 20% of treated individuals present the 15% or greater weight losses crucial to learn from significantly reduced risk of comorbidities, and a couple of. Within the yr following interventions, most patients experience a relapse in weight gain, mainly attributable to persistent metabolic adaptations, including increases in hunger hormones, decreases in satiety hormones, and reductions in overall energy expenditure.

In recent times, research has revealed incretin-based antiobesity medications as having the potential to surmount these limitations – Semaglutide 2.4 mg, a glucagon-like peptide-1 (GLP-1) receptor agonist, has been shown to lead to a 15% reduction in baseline body weight within the two years following intensive lifestyle interventions. Its mode of motion involves modifications of pathways governing the signaling of hunger and satiety in select neural regions, thereby stopping abnormal calorific intake.

Tirzepatide is a drugs currently approved for the treatment of type 2 diabetes mellitus (T2D). Administered via a subcutaneous injection, this single molecule combined the properties of semaglutide (GLP-1 receptor agonist) while providing the extra good thing about being a glucose-dependent insulinotropic polypeptide. Tirzepatide thereby provides synergistic antiobesity effects of reduced appetite, reduced energy intake, and improved metabolic function. While approved by the US of America (USA), the European Union (EU), and Japan for treating T2D, its use as an antiobesity intervention remains to be under review, with confounding results between studies.

In regards to the study

In the current study, researchers conducted a long-term (72-weeks), placebo-controlled randomized trial to elucidate the efficacy of tirzepatide following 12 weeks of intensive lifestyle interventions. The study lasted 84 weeks and was conducted in 62 medical research centers across the USA, Brazil, and Argentina. Participants were eligible in the event that they were adults over the age of 18 years and obese (body mass index [BMI] ≥ 30 kg/m²) or chubby (BMI ≥ 27 kg/m²) while also presenting at the very least one comorbidity of the conditions. Patients with preexisting diabetes mellitus (type 1 or 2) or who had lost greater than 5 kg body weight within the three months preceding the study were excluded.

Between 12 April 2021 and three September 2021, 972 participants were assessed for eligibility, of which 806 were enrolled. All enrolled participants were subject to 12 weeks of intensive lifestyle interventions (called the ‘lead-in’ period). The lead-in comprised reductions in calorific intake (1200 kcal for ladies, 1500 kcal for men), engaging in at the very least 150 minutes of physical activity per week (moderate intensity), and frequent face-to-face counseling sessions (eight sessions over 12 weeks). Participants were advised to finish 3-day long exercise and food regimen logs before each counseling session.

Participants who presented a weight reduction of 5 kg or greater by week 12 were enrolled for the second phase of the study – the 72-week-long trial involving using either the utmost tolerated dose (MTD) of tirzepatide (10 – 15 mg) or a placebo. Participants were assigned to either the case or control groups in a 1:1 ratio via computer-generated randomization, and all researchers and participants were blind to treatment project. The interventions were administered once weekly as a subcutaneous injection, with a starting dose of two.5 mg of tirzepatide increased by 2.5 mg every 4 weeks until MTD was attained.

Study findings

Of the 806 participants enrolled within the study, 579 (71.8%) presented weight reduction of 5 kg or greater (mean 6.9% weight reduction) by week 12 and were included within the tirzepatide trial. Most included participants were white (86.0%), female (62.9%), and had a mean age of 45.6 years. Medical characteristics included a mean obesity duration of 15.1 years, and 66.1% of participants presented a number of obesity-related comorbidities.

Blood pressure change from start of lead-in period over time. Panel A, mean (95% confidence interval) change from baseline over time in systolic blood pressure from start of intensive-lifestyle intervention lead-in period (week -12) to 72 weeks using observed means. Week 72 estimates for the efficacy estimand (EFF) are also shown. Panel B, mean (95% confidence interval) change from baseline over time in diastolic blood pressure from start of intensive-lifestyle intervention lead-in period (week -12) to 72 weeks using observed means. Week 72 estimates for the efficacy estimand (EFF) are also shown.

Statistical analyses revealed that a greater proportion of participants receiving tirzepatide interventions either lost additional weight or maintained ≥80% of weight lost through the lead-in period in comparison with the placebo group. These results are highlighted in efficacy statistics, revealing that 98.6% of case participants maintained the ≥80% endpoint versus only 37.8% of the placebo controls.

Case participants experienced a mean weight reduction of -26.6% at the tip of the 84-week-long study, in comparison with -3.8% within the control cohort. Correspondingly, the common BMI change of the case-cohort was −10.4 kg/m² in comparison with –1.4 kg/m² within the control cohort. Cardiometabolic health outcomes within the case-cohort were significantly improved, most notably in each systolic- and diastolic blood pressure, all fasting lipid levels, glycemic control, and fasting insulin levels.

“As well as, 4.9 and a couple of.8% of participants within the tirzepatide group compared with 1.0 and 1.7% of participants within the placebo group were reported as having a decrease in intensity of antihypertensive and lipid-lowering medications, respectively. Conversely, 2.4 and 0.3% of participants within the tirzepatide group were reported to have experienced a rise in intensity of antihypertensive and lipid-lowering therapies, respectively, compared with 6.5 and a couple of.1% of participants within the placebo group.”

Self-reported physical function was observed to be higher within the case-cohort compared to the control group. Nonetheless, tirzepatide was not without its shortcomings – 87.1% of treated patients reported treatment-emergent antagonistic effects, probably the most common of which were gastrointestinal, including diarrhea, nausea, and constipation. The severity was observed to be mild to moderate.

“Serious antagonistic events were reported by 31 participants (5.4%) overall. Occurrence was similar in participants treated with tirzepatide (5.9%) and placebo (4.8%). Two deaths (each myocardial infarction) were reported through the study, one within the tirzepatide MTD group and one within the placebo group. Each events were considered to not be related to the study treatment by the investigator.”

Conclusions

The current study aimed to guage the efficacy of tirzepatide as an antiobesity medication to advertise weight reduction and stop a relapse of weight gain in chubby and obese patients receiving intensive lifestyle interventions. The 84-week-long study revealed that tirzepatide MTD interventions resulted in significantly improved weight reduction in comparison with the placebo control group, corresponding improvements in cardiometabolic function, and reduced obesity-related comorbidities.

Mild to moderate negative effects were reported by 87.1% of participants, with serious negative effects reported by 5.9%. These negative effects were mainly gastrointestinal in nature and will be controlled by additional medication and dietary interventions. Future research investigating optimized, patient-specific dosages as a substitute of MTD may also improve these outcomes and reduce the antagonistic effects of this intervention.